RT Book, Section
A1 Jaleel, Tarannum
A1 Pollack, Brian P.
A1 Elmets, Craig A.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161346129
T1 Phototherapy
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161346129
RD 2024/04/19
AB AT-A-GLANCEThe  main  wavelengths  used  for  phototherapy  include  broadband  ultraviolet  B  (BB-UVB),  narrowband  UVB  (NB-UVB),  ultraviolet  A  (UVA)  1,  and  UVA  for  psoralen  photochemotherapy  (PUVA);  these  have  different  depths  of  penetration  and  interact  with  a  specific  range  of  molecules  rendering  unique  photobiologic  properties  with  respect  to  potency,  side  effects,  and  diseases  in  which  they  are  effective.Targeted  therapy  devices  can  deliver  distinct  wavelengths  of  ultraviolet  radiation  to  only  lesional  skin.  Such  devices  that  can  deliver  wavelengths  of  UVR  at  or  close  to  those  that  are  most  effective  at  clearing  localized  atopic  dermatitis,  psoriasis,  vitiligo,  and  cutaneous  T-cell  lymphoma  have  been  evaluated,  and  are  being  used  clinically.Sunburn-like  reactions  are  the  most  common  short  term  adverse  effect  of  phototherapy.  UVB  phototoxicity  usually  peaks  at  12  to  24  hours  and  PUVA  reaction  manifests  at  24  to  48  or  even  72  hours.  Importantly,  except  for  PUVA  therapy  for  which  formal  long  term  follow  up  studies  established  an  increased  risk  of  lentigines,  squamous  cell  carcinoma,  and  possibly  melanoma,  other  forms  of  phototherapy  appear  to  be  remarkably  safe.